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ABSTRACT
Existing clinical studies concerning the impact of therapy with third-generation cephalosporins or
cefepime on infections caused by extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae
are retrospective, non-randomised, and have been carried out with a small number of patients and
low-dosage schedules that lack PK-PD correlations with clinical efﬁcacy. Rates of clinical failure
and mortality are higher than those in studies with non-ESBL- producing Enterobacteriaceae. Therefore,
in settings with a high prevalence of ESBL-producing Enterobacteriaceae, empirical therapy
with advanced cephalosporins should be avoided. Temocillin, an old b-lactam that is stable in the
presence of both ESBLs and AmpC b-lactamases, seems to deserve revival, although clinical data are
limited.
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INTRODUCTION
Extended-spectrum b-lactamase (ESBL)-produc-
ing enterobacteriaceae are rapidly increasing in
importance as pathogens, in both intensive care
units and general medicine wards, as well as in
long-term care facilities [1] As of July 2006, almost
335 different ESBL types have been described
(http:1/www.lahey.org/studies/webt.htm). Re-
cently, the inﬂux of ESBL-producing enterobacte-
riaceae from the community into the hospital has
been attributed to ‘home care providers’ and
other factors that pose a public health threat, e.g.,
food production and distribution, animal farms
and sewage [2,3]. The MYSTIC study reﬂects
recent global trends in enterobacteriaceae
expressing the ESBL phenotype (Table 1) [1].
Previous administration of b-lactams contain-
ing an oxymino-group (cefuroxime, cefotaxime,
ceftriaxone, ceftazidime or aztreonam) represents
an independent and signiﬁcant risk-factor for
infection due to ESBL-producing bacteria [4].
Therapeutic options are limited because resis-
tance to third-generation cephalosporins is often
accompanied by that to ﬂuoroquinolones, tri-
methoprim–sulfamethoxazole, aminoglycosides
and tetracyclines. Even carbapenems, considered
to be the empirical therapy of choice, is
threatened by the simultaneous production of
metallo-b-lactamase enzymes, as has been
recently reported [5]. ESBLs are connected with
increased rates of mortality, length of hospital
stay, delay in appropriate therapy and hospital
cost [4]. These facts led the former NCCLS to
develop strict guidelines for uniform standards
for screening and conﬁrmatory testing for ESBL
production [4,6].
THE THERAPEUTIC ROLE OF THIRD-
GENERATION CEPHALOSPORINS
ESBLs vary in their ability to hydrolyse third-
generation cephalosporins. An ESBL-producing
microorganism may require an MIC of ceftazi-
dime of >250 mg ⁄L, while the MIC of ceftriaxone
or cefotaxime may be £8 mg ⁄L, leading to an
inappropriate choice of therapy [7]. In a recent
study of 455 consecutive episodes of Klebsiella
pneumoniae bacteraemia in 12 hospitals from
seven countries, 85 episodes were attributed to
ESBL-bearing strains. Failure to administer an
active antibiotic was associated with a signiﬁ-
cantly higher mortality rate (63.6%) than was
Corresponding author and reprint requests: H. Giamarellou,
4th Department of Internal Medicine, Athens University
Hospital ‘ATTIKON’, 1 Rimini Street, 124 62 Athens, Greece
E-mail: hgiama@ath.forthnet.gr
 2008 The Author
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 194–197
treatment with active antibiotics (14.1%)
(p 0.001). In a similar study in paediatric patients,
the respective mortality rates were 26.7% vs.
5.7% (p 0.01) [7,8]. In a multicentre international
study that analysed 36 cases of serious infections
due to ‘apparently cephalosporin susceptible’
organisms producing ESBLs, 100% (four of four)
of the patients failed when the MICs were in the
intermediate range (16–32 mg ⁄L) and 54% (15 of
28) failed when the MICs were in the susceptible
range (£8 mg ⁄L) [9]. Failure rates were highest
(100%; six of six) in patients infected with
organisms for which the MIC of the cephalospo-
rin prescribed was 8 mg ⁄L and lowest in patients
(27%; three of 11) infected with organisms for
which the MIC was £1 mg ⁄L. An apparently
signiﬁcant increase in the failure rate was
observed as the MICs rose within the ‘susceptible’
range (p 0.004). The authors concluded that it is
clinically important to detect ESBL production by
Klebsiella or Escherichia coli even when cephalo-
sporin MICs are low and to report ESBL-produc-
ing organisms as resistant to aztreonam and all
cephalosporins [9]. In a subset analysis of Korean
children who were bacteraemic due to E. coli (15)
and K. pneumoniae (34) and treated with ex-
tended-spectrum cephalosporins, with or without
an aminoglycoside, favourable response rates
were signiﬁcantly more frequent in the non-ESBL
group by the third day (64.7% vs. 7.2%, p 0.035),
or the ﬁfth day (34.6% vs. 7.2%, p 0.05) and at the
end of therapy (94% vs. 5.3%, p <0.001) [8].
In a Chinese study among patients with bacter-
aemia due to ESBL producers, those treated with
imipenem were more likely to survive, while
those treated with a cephalosporin tended to have
a poorer outcome (1 ⁄ 19 died vs. 14 ⁄ 40, p 0.023)
[10]. In a recently published study from Korea,
examining 25 patients with bacteraemia caused by
ESBL-producing E. coli and K. pneumoniae, the
proportion that failed on empirical cephalosporin
therapy rose from 16.6% to 73.6% as MICs rose
from £2 to ‡8–32 mg ⁄L [11]. Finally, the results of
a recent Italian study on the clinical outcome of 48
patients infected with ESBL-producing K. pneu-
moniae are presented in Table 2 [12]. Empirical
therapy was inadequate in 24 patients, 17 of
whom received an oxymino-cephalosporin, ﬁve a
ﬂuoroquinolone and two a b-lactam–b-lactamase
inhibitor combination.
The high mortality rates reported in several
studies, which are attributed to inadequate ther-
apy, indicates the need for sounder and more
effective policies and guidelines [7–12]. Reduction
and restriction in the use of third-generation
cephalosporins is the common theme underlying
many successful interventions to reverse the
increase in ESBL-producing K. pneumoniae [13].
Efforts to enforce strict hand hygiene rules should
supplement antibiotic restriction policies [13].
CEFEPIME: DOES IT BEHAVE
IN VITRO AND IN VIVO LIKE
A THIRD-GENERATION
CEPHALOSPORIN?
Cefepime is a fourth-generation cephalosporin
that seems to be more stable to some ESBLs, and
is very stable to AmpC-type b-lactamases.
However, CTX-M-type ESBLs, which are of grow-
ing importance, hydrolyse cefepime efﬁciently,
Table 1. Percentage of organisms expressing extended-
spectrum b-lactamase (ESBL) phenotype in the meropenem
yearly susceptibility test information collection (MYSTIC)
study, 1997–2003 [1]
Isolates with ESBL phenotype
Escherichia coli
(%)
Klebsiella
pneumoniae
(%)
Proteus
mirabilis
(%)
North America 7.5 12.3 3.9
South America 18.1 51.9 6.2
Northern Europe 16.2 16.7 5.9
Southern Europe 16.0 24.4 20.5
Eastern Europe 28.9 58.7 21.3
Asia-Paciﬁc 14.2 28.2 23.7
Table 2. Clinical outcomes of patients with bacteraemia
caused by extended-spectrum b-lactamase (ESBL)-produc-
ing Klebsiella pneumoniae isolates vs. those of patients with
bacteraemia caused by non-ESBL-producing K. pneumoniae
isolates [12]
Outcome
Percentage of patients with the
indicated outcome
ESBL
group
(n = 48; %)
Non-ESBL
group
(n = 99; %) p
Recovery 48 71 0.007
Initial treatment failure 31 17 0.05
Death at 7 days 25 11 0.03
Death at 21 days 52 29 0.007
Overall mortality 67 37 0.04
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suggesting that continuous monitoring of cefe-
pime susceptibilities and ESBL characteristics is
very important.
Susceptibility results for 281 urine isolates of
ESBL-producing K. pneumoniae strains from 15
Brooklyn hospitals showed MIC50 and MIC90
values of 1 and 16 mg ⁄L vs. >32 and >32 mg ⁄L
for cefepime and ceftazidime, respectively [14].
However, an eight-fold or greater MIC arose
when the innoculum was raised to 107 CFU ⁄mL
with cefepime and cefotaxime, with MIC90s
exceeding 128 and 1024 mg ⁄L, respectively [15].
The pharmacodynamics of intermittent and
continuous infusion of cefepime against ESBL-
producing organisms showed that continuous
infusion of 4 g per day had the highest probability
of target attainment (77%), followed by 1 g every
8 h (65%), 2 g every 12 h (58%), continuous
infusion of 3 g (46%) and 1 g every 12 h (27%),
taking into account that time above the MIC
(%T>MC) for the intermittent bolus regimen
should be ‡60% with a desired concentration at
the steady state (Css ⁄MIC) ratio of ‡2 for all
continuous infusion regimens [16]. On this basis,
it has been suggested that cefepime should not
be used routinely for treating infections due to
ESBL producers [16].
The literature concerning the clinical use of
cefepime against ESBL-producing pathogens is
limited and controversial. It is of interest that after
a formulary change to cefepime, the use of
ceftazidime and cefotaxime decreased by 89%
without selecting ESBL-producing strains; rather,
a signiﬁcant decrease in infections due to ceftaz-
idime-resistant K. pneumoniae and Pseudomonas
aeruginosa was observed [17]. However, these
epidemiological data cannot hide the limited
therapeutic outcome of cefepime in the treatment
of infections caused by ESBL-producing patho-
gens. Among six cases of bacteraemia following
major surgical procedures and treatment with
cefepime, only one patient survived, whereas,
among 27 patients with a variety of serious
infections caused by ESBL-producing E. coli and
Klebsiella spp., bacteriological eradication ranged
from 37.5% to 83%, with simultaneous clinical
cure rates of 90% for urinary tract infections and
76% for lower respiratory tract infections (LRTI).
However, only 45% of the bacteraemic patients
had successful outcomes [18]. Goethaert et al.
evaluated retrospectively the efﬁcacy of high-dose
cefepime (2 g ⁄ 8 h) vs. a carbapenem in 44 patients
suffering from serious intensive care unit infec-
tions caused by TEM-24-producing Enterobacter
aerogenes [19]. In 12 out of 29 patients, amikacin
was co-administered. Clinical improvement was
similar (62% vs. 70%) but bacteriological eradica-
tion was low (14% vs. 23%); and a statistically
signiﬁcant increase in failure to eradicate patho-
gens was observed as the MIC of cefepime rose
(p 0.017). Finally, a recent retrospective study in
which cefepime was given to ten patients with
non-urinary tract infections caused by ESBL-pro-
ducing enterobacteriaceae at a dose of 1 g every
12 h, with 20 case-controls, concluded that pa-
tients receiving cefepime for an infection due to an
ESBL producer were 9.7 and 28.5 times as likely to
have an unsuccessful clinical and microbiological
response as those infected with a non-ESBL
producer [20].
In summary, it is evident that the clinical
effectiveness of cefepime against ESBL-producing
enterobacteriaceae is not well-elucidated, due to
small and retrospective studies, to the low dosage
prescribed, to different endpoints, and to the
absence of pharmacokinetic–pharmacodynamic
correlations with efﬁcacy. Nevertheless, it can be
said that cefepime should not be used as ﬁrst-line
therapy against ESBL-producing pathogens. If,
contrary to this advice, it is prescribed, it should
be given in high doses, preferably in combination
with an aminoglycoside [21].
TEMOCILLIN
Temocillin is the 6-a-methoxy derivative of
ticarcillin. This modiﬁcation increases stability to
b-lactamases, including AmpC and ESBLs, but
reduces activity against P. aeruginosa and elimi-
nates afﬁnity for the essential penicillin-binding
proteins of Gram-positive bacteria and Bacteroides
spp., giving a narrow-spectrum agent with
very consistent bactericidal activity against
enterobacteriaceae [22]. Temocillin was marketed
in the 1980s by Beecham Pharmaceuticals in the
UK, but achieved little commercial success and
was withdrawn. It continues to be marketed
in Belgium. Recently, it was re-licensed by
Eumedica in the UK [23].
Based on a Cmax of 160 mg ⁄L and T1 ⁄ 2 of 5 h
with 85% serum protein binding after a 2-g
intravenous dose, a susceptibility breakpoint of
£16 mg ⁄L has been applied [23]. Among 846
enterobacteriaceae, >88% of the ESBL producers
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were found to be susceptible, and 99% were
inhibited at £32 mg ⁄L [23]. Clinical experience,
however, is limited. One recent open-label Bel-
gian study described clinically successful use of
temocillin in 25 of 26 patients with urinary
infections caused by multiresistant E. aerogenes
strains, most of which were ESBL producers. Six
of the seven patients without severe sepsis caused
by multiresistant E. aerogenes were cured [24].
CONCLUSION
It is evident that, in settings with a high
prevalence of ESBL-producing Enterobacteria-
ceae, advanced cephalosporins should not be
recommended for empirical use. Likewise, these
agents should not be used in infections due to
conﬁrmed ESBL producers. On the other hand,
temocillin deserves further attention via well-
controlled studies in patients in whom ESBL-
producing pathogens are implicated.
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